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It has been well established that T cells recognize foreign antigens in conjunc-
tion with products of the major histocompatibility complex (MHC) that are
expressed on the surface of most cells (1). The question has been raised whether
B cells and their products may recognize foreign antigen together with MHC
antigens. Wylie et al . (2) have shown that influenza A virus-infected cells are
recognized by monoclonal or oiigoclonal antibodies in >50-70% of all examples
only if the H-2 K/D region products are shared between the infected tumor cells
or in vitro-cultured cells that were used for the induction of the B cell response
and the infected cells that were used in the binding assay for antibody specificity.
Comparable results have been obtained in a study (3) using simian virus 40
(SV40)-transformed tissue culture cell lines.
We investigated the specificity of monoclonal antibodies against the natural
mouse pathogen lymphocytic choriomeningitis virus (LCMV). Monoclonal anti-
bodies derived from 13 fusions of lymphocytes 6-13 d after initiation of a
primary infection with myeloma cells were analyzed to evaluate whether MHC-
restricted antiviral antibodies are frequent and therefore probably of biological
relevance.
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Materials and Methods
BriefDefinitive Report
Mice, Virus, Immunization and Fusion.
￿
C57BL/6J (H-2b) and C3H/HeJ (H-2k) male and
female mice were purchased from the Institut für Zuchthygiene, Tierspital, Universitiit
Zurich. LCMV WE was originally obtained from Dr. F. Lehmann-Grube, Hamburg,
Federal Republic of Germany, and LCMV Armstrong from Dr. M . B. A. Oldstone,
Scripps Clinic and Research Foundation, La Jolla, CA (1). The fusion of lymphoid cells
with FO or Ag 8.653 cells was carried out according to standard procedures (4, 5).
Radioimmunoassay (RIA).
￿
A two-step RIA using '25I-labelled anti-mouse Ig or three-
step assays with either '25Wabelled protein A or with biotinylated anti-mouse Ig and'25I-
labelled streptavidin were used to determine positive hybridoma supernatants. Briefly,
virus-infected or -uninfected tissue culture cells were added at a concentration of 1-2 X
104 cells/well in 50 g1 of RIA buffer PBS (1% BSA, 0.2% azide) to 50 ul of hybridoma
supernatants. For hybridoma supernatants from group I (Table 1), Mc57G (H-2 ) and D2
(H-2d) cells were used for the screening and for group 11 supernatants, Mc57G and L929
(H-2') cells were used. After the addition of the cellsto the supernatants, the preparations
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TABLE I
Summary ofAllFusion Experiments Carried Outwith Lymphoid Cellsfrom
LCMV-infectedMice
* Mice were injected into the footpad.
t Inguinal lymph nodes were used for the fusions.
0 Mice received a booster injection 3 d before the fusion was carried out.
were incubated for 2 h at 4° C, and then washed three times before 3-5 X 105 cpm of
1251-labelled compounds were added. After a further incubation of 2 h at 4°C, cells were
washed repeatedly and radioactivity was determined. Binding of supernatants was consid-
ered to be positive if the absolute counts exceeded twice the background value, which
was defined as the mean of 20% of the lowest values of all supernatants of the same plate.
Those positive values always corresponded to >3-5 SD above the background value given
by irrelevant monoclonal antibodies.
In all tests the following positive controls were included: monoclonal anti-LCMV IgG
antibodies 6.2 and 24.A (kindly provided by Dr. M. Buchmeier, Scripps Clinic, La Jolla,
CA [6, 7]) and monoclonal anti-Kb and anti-Kk antibodies.
Immunofuorescence.
￿
Mc57G, L929, and D2 cells were infected with LCMV and were
either used without further treatment for determination of viral surface antigens or were
grown on microscope-slides and then fixed in ice-cold acetone for detection of intracellular
viral antigens. A 1 :50 dilution of FITC-labelled goat anti-mouse Ig (Tago, Burlingame,
CA) was used as second antibody. Thereafter cells were again washed repeatedly and
scored for fluorescence under an inverted UV-light microscope. Two LCMV-specific
monoclonal antibodies were used as a positive control for surface (6.2) (6) or internal viral
antigens (24,A) (7). All hybridoma supernatants were also scored additionally on unin-
fected cells.
Results and Discussion
A total of 830 hybridomas were obtained after fusion of lymphoid cells from
mice infected with LCMV for various times and were analyzed (Tables I and 1I).
As indicated in Table 11, all supernatants were first screened by cell RIA for
reactivity on LCMV-infected Mc57G cells. The results show that 5-20% of all
supernatants from growing hybridomas reacted with LCMV-infected cultured
Group Mouse
strain
Virus strain Infectious
dose
Route
of
infec-
tion
Day of infec-
tion
Source
of
cells
Myeloma
cell
Number of
growing
hybridomas
PFU/mouse
1 C57BL/6 WE 2 x 105 i.v. -6 Spleen FO 124
2 x 10* i.v. -5 Spleen FO 17
2 x 104 i.v. -13 Spleen FO 254
2 x 105 i.v. -13 Spleen FO 230
2 x 10" i.f.* -4 IN* FO 6
2 x 105 i.f. -4 IN Ag 8.653 171
2 x 104 i.f. -5 IN Ag 8.653 21
2 x 105 i.f. -5 IN FO 7
Total: 830
11 C57BL/6 Armstrong 2 x 105 i.v. -5 Spleen FO 145
C57BL/6 -10 231
C3H -5 49
C3H -10 74
C57BL/6 -14 and -34 2
C57BL/6 -21 and -3 3
C3H -14 and -3 1
C3H -21 and -3 9
Total: 514Group
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* Estimated as positive if absolute counts on infected cells exceeded twice the background value of control
superantants (see Materials and Methods).
$ Binding specificity tested on infected vs. uninfected Mc57G (H-2") cells.
: Crossreactivity tested on infected D2 (H-2') or L929 (H-2`) cells.
Tested on acetone-fixed monolayer cells.
'Suspended cells were incubated with supernatants in the presence of 1% BSA and 0.2% azide at room
temperature.
** All non-crossreactive supernatants subsequently showed loss of virus specificity.
cells. When these positive supernatants were further tested a high percentage
wasfound that showed fluorescence on both infected and uninfected cells. These
supernatants were excluded from thestudy and only the remaining supernatants
that showed fluorescence exclusively on infected cells were regarded as specific
for LCMV (Table 11). These supernatants were however also reactive when
tested on infected vs. uninfected allogeneic D2 (H-2d; Table 11, group 1) or on
the respective infected allogeneic target cells of group II. Essentially, the same
results were obtained ifhybridoma supernatants were tested in a cellular ELISA
test (not shown). If supernatants were Iurt?!er tested for fluorescence on virus-
infected acetone-fixed monolayer cells or on unfixed live cells, only 5 out of 11
supernatants positive by RIA on infected syn- and allogeneic cells showed specific
reactivity. However, all of these supernatants showed positive reaction on all
tested infected cells, irrespective ofthe H-2 haplotype (Table 11, group 1).
At least two questions are raised by our results that differ from the reports
claiming that antibodies frequently bind to viral antigens only in association with
the correct MHC determinant. First, are the differences in the analytical ap-
proach, both at the level of induction and ofantibody detection, responsible for
the data obtained and, second, what is the biological significance ofthe findings?
In contrast to the present study, other workers immunized mice with virus-
infected tumor cell lines (2) or virus-transformed tissue culture cell lines (3) to
induce T help for the induction of B cells in an adoptive transfer model. We
could not find examples of MHC-restricted antibodies against LCMV when we
Specificity ofSupernatants Tested by RIA and Immunofluorescence
Growing
hybridomas
Positive
superna-
Virus-specificity
on syngeneic
Virus-specificity
on allogeneic on
Virus-specificity
fixed cellst
Virus-specif
on living cells:
city
Mc57G tants* cells= cells Mc57G D2 L929 and L929
124 15 Mc57G 2 D2 2** 0 0 0 0
17 0 Mc57G 0 - - - -
254 27 Mc57G 4 D2 2 2 2 2 2
230 24 Mc57G 3 D2 3 3 3 3 3
6 2 Mc57G 1 D2 1 0 0 0 1
171 16 Mc57G 4 D2 3** 0 0 0 1
21 1 Mc57G 0 - - - -
7 0 Mc57G - - - - -
Total: 830 80 14
145 29 Mc57G I L929 1
231 36 Mc57G 5 L929 4
49 3 L929 0 -
74 7 L929 1 Mc57G 1
2 0 Mc57G - -
3 2 Mc57G 0 -
1 0 L929 - -
9 1 L929 u -
Total: 514 78 7298
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used live infected cells for the RIA or immunofluorescence studies. The discrep-
ancies could be caused by the use ofinfected fixed cells for the RIA and the use
ofa relatively low technical cutoff point (>3 SD above background) for accepting
RIA results as positive. This could have led to the detection of(weak) cell-surface
determinants that are not really characteristic for the infecting virus and may be
influenced by the fixation procedure (8). Furthermore, formal proof that the
antibodies are really specific for virally induced cell surface antigens is lacking in
both the influenza model (2) and the SV40 model (3), because antibodies that
bind to purified virus and to infected cells were not further analyzed, since they
are MHC-unrestricted. Similarly, SV40-transformed fibroblast cell lines may
express many possible antigenic determinants and variants that may be related
to SV40 transformation but characteristic for the individual cell clone rather
than its particular H-2. The fact that in the SV40 study only one out of eight or
nine antibodies shared the same specificity pattern may support this possibility.
Our results are in agreement with two reports that did not find any evidence
for MHC-restricted antiviral antibodies after immunization of mice with synge-
neic Sendai virus-infected spleen cells (9) or with influenza A virus-infected
syngeneic EL-4 cells (10).
We therefore feel that the evidence that MHC-restricted virus-specific anti-
bodies exist cannot be generalized, and that they may possibly be artifacts on
technical grounds or rare examples. Ouranalysisofthe antibody response during
a primary or secondary infection with LCMV, a naturally occurring infectious
disease in mice, suggests that antibodies specific for viral antigenic determinant
are specific for this determinant independent of MHC determinants.
Summary
Monoclonal antibodies against lymphocytic choriomeningitis virus (LCMV), a
natural, high-replicating, noncytolytic pathogen in mice, were obtained from
fusions between myeloma cells and lymphoid cells of mice of different H-2
haplotypes at various times (4-24 d) after infection.
Supernatants from growing hybridomas were tested in a RIA, and ^-15% of
all supernatants were positive when tested for specificity on infected vs. unin-
fected cells ofdifferenthaplotypes. Upon retesting for specific fluorescence, only
some RIA' supernatants exhibited specific surface staining of acetone-fixed
infected cells or unfixed infected cells. In all these experiments and usingvarious
detection methods we could not find antibodies with any preference of recogni-
tion of viral antigen in conjunction with the H-2 haplotype of the responder
mouse.
The absence of H-2 restricted antibodies after a primary virus infection in
vivo, whether assayed by RIA or surface immunofluorescence, suggests that
antibodies obtained in other experiments (2, 3) using infected tumor cells for
induction and in the RIA may not represent the general case.
Receivedforpublication 17 February 1987 and in revisedform 29 April 1987.
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